VijayPD Ceutical Limited deploys Rs 19.25 crore IPO with no deviation
Key highlights
- VijayPD Ceutical reported full utilisation of Rs 19.25 crore of IPO proceeds by September 30, 2026.
- VijayPD Ceutical allocated Rs 10.83 crore to plant construction and machinery capital expenditure.
- VijayPD Ceutical used Rs 5.10 crore of IPO proceeds for repayment or prepayment of borrowings.
- J D Shah Associates certified on November 14, 2026 that the utilisation statement agreed with company records.
powered by IRIS

VijayPD Ceutical Limited reported full use of its Rs 19.25 crore initial public offer (IPO) proceeds by September 30, 2026, with no deviation from its stated objects. The largest use was Rs 10.83 crore for construction and machinery at a proposed pharmaceutical manufacturing plant in Shrirampur, Maharashtra.
Know Vijaypd Ceutical inside out
Results, valuation, peers and who's buying, in one view.
How did VijayPD Ceutical use its IPO proceeds?
VijayPD Ceutical used all four disclosed IPO allocations totalling Rs 19.25 crore by September 30, 2026. It reported Rs 10.83 crore for capital expenditure, Rs 5.10 crore for repayment or prepayment of borrowings, Rs 74.17 lakh for general corporate purposes and Rs 2.58 crore for issue-related expenses.
The IPO was a fresh issue of 55 lakh equity shares with a face value of Rs 10 each and a premium of Rs 25 each. The company reported September 29, 2025 as the fund-raising date, and said its shares were listed on the SME Platform of NSE Limited on October 7, 2025.
The Rs 10.83 crore capital-expenditure object covered construction of a pharmaceutical active pharmaceutical ingredients (API), intermediates and chemicals manufacturing plant, along with purchases of new machinery. The disclosed project location is MIDC Shrirampur in Ahmednagar, Maharashtra.
Was there any variation in VijayPD Ceutical's IPO fund use?
No, VijayPD Ceutical reported zero deviation or variation for each of its four IPO objects for the period ended September 30, 2026. The statement's overall response to whether there was a deviation or variation in the use of raised funds was “No”, with no modified objects or modified allocations recorded.
The original allocation and utilisation for capital expenditure were both Rs 10.83 crore, while both figures were Rs 5.10 crore for debt repayment or prepayment. The same match applied to Rs 74.17 lakh for general corporate purposes and Rs 2.58 crore for issue-related expenses, with Rs 0 deviation against every category.
The filing defines a deviation or variation as a change in the objects or purposes for which funds were raised, or a change in terms of a contract referred to in the fund-raising document. It listed no shareholder approval date, rationale, Audit Committee comments or auditor comments in fields applicable to a variation.
What did the auditor conclude on VijayPD Ceutical's utilisation statement?
J D Shah Associates concluded that VijayPD Ceutical's utilisation statement agreed with its books of account and records and fairly presented, in all material respects, the use of public-issue funds. The certificate is dated November 14, 2026 and accompanied the statement for the period ended September 30, 2026.
The firm said its examination followed the Institute of Chartered Accountants of India's 2016 Guidance Note on Reports or Certificates for Special Purposes. It also reported compliance with Standard on Quality Control 1, the quality-control standard for firms carrying out audit, review and assurance engagements.
The certificate was addressed to the Audit Committee to support its obligations under the Listing Obligations and Disclosure Requirements regulations. J D Shah Associates also restricted use of the certificate to that purpose and stated that it did not accept responsibility to other users without prior written consent.
Got a follow-up? Ask IRIS
What do VijayPD Ceutical's September 2026 accounts show alongside the deployment?
VijayPD Ceutical reported property, plant and equipment of Rs 5.31 crore at September 30, 2026, compared with Rs 5.19 crore at March 31, 2026. Capital work-in-progress rose to Rs 4.29 crore from Rs 1.66 crore over the same period, an increase of Rs 2.63 crore.
Those balance-sheet changes are not presented as a direct reconciliation of the Rs 10.83 crore IPO capital-expenditure allocation. They were reported alongside the full utilisation disclosure for construction and machinery at the Shrirampur project.
Total borrowings, combining long-term and short-term borrowings, were Rs 49.13 crore at September 30, 2026, versus Rs 36.71 crore at March 31, 2026. This increase occurred despite the reported Rs 5.10 crore use of IPO proceeds for debt repayment or prepayment, showing that the use-of-proceeds statement does not itself explain later changes in borrowings.
Cash and cash equivalents declined to Rs 1.95 crore at September 30, 2026 from Rs 17.52 crore at March 31, 2026. The cash-flow statement reported Rs 25.14 crore of net cash used in operating activities, Rs 1.10 crore used in investing activities and Rs 10.67 crore generated from financing activities during the period shown.
Why does full deployment matter for VijayPD Ceutical's stated IPO objects?
Full deployment means VijayPD Ceutical reported that no part of the Rs 19.25 crore fresh issue remained unassigned to its four disclosed objects as of September 30, 2026. Capital expenditure accounted for Rs 10.83 crore of the total, while debt repayment or prepayment accounted for Rs 5.10 crore.
The company distinguished its IPO-use statement from its wider financial reporting. In notes to its consolidated results for the half year ended September 30, 2026, it said the group was exclusively engaged in pharmaceutical trading and had no separate reportable segment under Accounting Standard 17.
VijayPD Ceutical's Audit Committee reviewed, and its board approved, the consolidated unaudited financial results on November 14, 2026. Its statutory auditors expressed an unmodified conclusion on those results, while the separate certificate considered whether the IPO utilisation statement agreed with company records.
Conclusion
VijayPD Ceutical disclosed that it had deployed the full Rs 19.25 crore IPO amount across its original four uses, with Rs 10.83 crore assigned to the plant and machinery objective and Rs 5.10 crore to debt repayment or prepayment. The company reported no object-wise variation, and J D Shah Associates said the utilisation statement agreed with its books and records.
The disclosed item to watch next is execution of the Shrirampur plant-construction and machinery plan supported by the Rs 10.83 crore capital-expenditure allocation. Later financial statements may provide updates through capital work-in-progress, which was Rs 4.29 crore at September 30, 2026, property and equipment, borrowings and cash balances.


